Join Growin Stock Community!

Abbvie inc.ABBV.US Overview

US StockHealthcare
(No presentation for ABBV)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ABBV AI Insights

ABBV Overall Performance

ABBV AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ABBV Recent Performance

0.50%

Abbvie inc.

0.05%

Avg of Sector

-0.31%

S&P500

ABBV PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ABBV Key Information

ABBV Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ABBV Profile

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Price of ABBV

ABBV FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ABBV Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.39
PE Ratio (TTM)
97.92
Forward PE
16.68
PS Ratio (TTM)
6.71
PB Ratio
50.46
Price-to-FCF
23.15
METRIC
VALUE
vs. INDUSTRY
Gross Margin
70.24%
Net Margin
6.91%
Revenue Growth (YoY)
8.57%
Profit Growth (YoY)
8.94%
3-Year Revenue Growth
3.20%
3-Year Profit Growth
3.28%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.39
PE Ratio (TTM)
97.92
Forward PE
16.68
PS Ratio (TTM)
6.71
PB Ratio
50.46
Price-to-FCF
23.15
Gross Margin
70.24%
Net Margin
6.91%
Revenue Growth (YoY)
8.57%
Profit Growth (YoY)
8.94%
3-Year Revenue Growth
3.20%
3-Year Profit Growth
3.28%

  • When is ABBV's latest earnings report released?

    The most recent financial report for Abbvie inc. (ABBV) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ABBV's short-term business performance and financial health. For the latest updates on ABBV's earnings releases, visit this page regularly.

  • Where does ABBV fall in the P/E River chart?

    According to historical valuation range analysis, Abbvie inc. (ABBV)'s current price-to-earnings (P/E) ratio is 94.06, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of ABBV?

    According to the latest financial report, Abbvie inc. (ABBV) reported an Operating Profit of 4.54B with an Operating Margin of 27.34% this period, representing a growth of 404.97% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ABBV's revenue growth?

    In the latest financial report, Abbvie inc. (ABBV) announced revenue of 16.62B, with a Year-Over-Year growth rate of 10.04%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ABBV have?

    As of the end of the reporting period, Abbvie inc. (ABBV) had total debt of 67.5B, with a debt ratio of 0.5. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ABBV have?

    At the end of the period, Abbvie inc. (ABBV) held Total Cash and Cash Equivalents of 5.23B, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ABBV go with three margins increasing?

    In the latest report, Abbvie inc. (ABBV) achieved the “three margins increasing” benchmark, with a gross margin of 72.6%%, operating margin of 27.34%%, and net margin of 10.9%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ABBV's profit trajectory and future growth potential.

  • Is ABBV's EPS continuing to grow?

    According to the past four quarterly reports, Abbvie inc. (ABBV)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.02. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ABBV?

    Abbvie inc. (ABBV)'s Free Cash Flow (FCF) for the period is 4.89B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 27.65% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ABBV?

    The latest valuation data shows Abbvie inc. (ABBV) has a Price-To-Earnings (PE) ratio of 94.06 and a Price/Earnings-To-Growth (PEG) ratio of 0.06. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.